BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 30150718)

  • 1. The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space.
    Klughammer J; Kiesel B; Roetzer T; Fortelny N; Nemc A; Nenning KH; Furtner J; Sheffield NC; Datlinger P; Peter N; Nowosielski M; Augustin M; Mischkulnig M; Ströbel T; Alpar D; Ergüner B; Senekowitsch M; Moser P; Freyschlag CF; Kerschbaumer J; Thomé C; Grams AE; Stockhammer G; Kitzwoegerer M; Oberndorfer S; Marhold F; Weis S; Trenkler J; Buchroithner J; Pichler J; Haybaeck J; Krassnig S; Mahdy Ali K; von Campe G; Payer F; Sherif C; Preiser J; Hauser T; Winkler PA; Kleindienst W; Würtz F; Brandner-Kokalj T; Stultschnig M; Schweiger S; Dieckmann K; Preusser M; Langs G; Baumann B; Knosp E; Widhalm G; Marosi C; Hainfellner JA; Woehrer A; Bock C
    Nat Med; 2018 Oct; 24(10):1611-1624. PubMed ID: 30150718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiplex mapping of chromatin accessibility and DNA methylation within targeted single molecules identifies epigenetic heterogeneity in neural stem cells and glioblastoma.
    Nabilsi NH; Deleyrolle LP; Darst RP; Riva A; Reynolds BA; Kladde MP
    Genome Res; 2014 Feb; 24(2):329-39. PubMed ID: 24105770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of
    Brandes AA; Franceschi E; Paccapelo A; Tallini G; De Biase D; Ghimenton C; Danieli D; Zunarelli E; Lanza G; Silini EM; Sturiale C; Volpin L; Servadei F; Talacchi A; Fioravanti A; Pia Foschini M; Bartolini S; Pession A; Ermani M
    Oncologist; 2017 Apr; 22(4):432-437. PubMed ID: 28275120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence.
    Nickel GC; Barnholtz-Sloan J; Gould MP; McMahon S; Cohen A; Adams MD; Guda K; Cohen M; Sloan AE; LaFramboise T
    PLoS One; 2012; 7(4):e35262. PubMed ID: 22536362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analyzing DNA Methylation Patterns During Tumor Evolution.
    Pan H; Elemento O
    Methods Mol Biol; 2018; 1711():27-53. PubMed ID: 29344884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.
    Kim H; Zheng S; Amini SS; Virk SM; Mikkelsen T; Brat DJ; Grimsby J; Sougnez C; Muller F; Hu J; Sloan AE; Cohen ML; Van Meir EG; Scarpace L; Laird PW; Weinstein JN; Lander ES; Gabriel S; Getz G; Meyerson M; Chin L; Barnholtz-Sloan JS; Verhaak RG
    Genome Res; 2015 Mar; 25(3):316-27. PubMed ID: 25650244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
    Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
    Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification.
    Wenger A; Ferreyra Vega S; Kling T; Bontell TO; Jakola AS; Carén H
    Neuro Oncol; 2019 May; 21(5):616-627. PubMed ID: 30668814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spatial progression and molecular heterogeneity of IDH-mutant glioblastoma determined by DNA methylation-based mapping.
    Lyon JF; Vasudevaraja V; Mirchia K; Walker JM; Corona RJ; Chin LS; Tran I; Snuderl M; Richardson TE; Viapiano MS
    Acta Neuropathol Commun; 2021 Jun; 9(1):120. PubMed ID: 34193272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.
    Schäfer N; Gielen GH; Rauschenbach L; Kebir S; Till A; Reinartz R; Simon M; Niehusmann P; Kleinschnitz C; Herrlinger U; Pietsch T; Scheffler B; Glas M
    J Transl Med; 2019 Mar; 17(1):96. PubMed ID: 30894200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.
    Kurdi M; Shafique Butt N; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Al-Sinani T; Alghanmi N; Bari MO; Samkari A; Lary AI
    Pathol Oncol Res; 2021; 27():1609778. PubMed ID: 34257620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epigenetic landscape of Alu repeats delineates the structural and functional genomic architecture of colon cancer cells.
    Jordà M; Díez-Villanueva A; Mallona I; Martín B; Lois S; Barrera V; Esteller M; Vavouri T; Peinado MA
    Genome Res; 2017 Jan; 27(1):118-132. PubMed ID: 27999094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular subtypes of glioma identified by genome-wide methylation profiling.
    Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ
    Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide investigation of intragenic DNA methylation identifies ZMIZ1 gene as a prognostic marker in glioblastoma and multiple cancer types.
    Mathios D; Hwang T; Xia Y; Phallen J; Rui Y; See AP; Maxwell R; Belcaid Z; Casaos J; Burger PC; McDonald KL; Gallia GL; Cope L; Kai M; Brem H; Pardoll DM; Ha P; Green JJ; Velculescu VE; Bettegowda C; Park CK; Lim M
    Int J Cancer; 2019 Dec; 145(12):3425-3435. PubMed ID: 31373686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA Methylation Analysis.
    Feng L; Lou J
    Methods Mol Biol; 2019; 1894():181-227. PubMed ID: 30547463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioblastoma Recurrence and the Role of O
    Storey K; Leder K; Hawkins-Daarud A; Swanson K; Ahmed AU; Rockne RC; Foo J
    JCO Clin Cancer Inform; 2019 Feb; 3():1-12. PubMed ID: 30758983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status.
    Chen WJ; Zhang X; Han H; Lv JN; Kang EM; Zhang YL; Liu WP; He XS; Wang J; Wang GH; Yu YB; Zhang W
    Cell Death Dis; 2020 Aug; 11(8):668. PubMed ID: 32820151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations.
    Jurmeister P; Wrede N; Hoffmann I; Vollbrecht C; Heim D; Hummel M; Wolkenstein P; Koch I; Heynol V; Schmitt WD; Thieme A; Teichmann D; Sers C; von Deimling A; Thierauf JC; von Laffert M; Klauschen F; Capper D
    J Pathol; 2022 Jan; 256(1):61-70. PubMed ID: 34564861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole Genome DNA Methylation Analysis of Human Glioblastoma Using Illumina BeadArrays.
    Serrano J; Snuderl M
    Methods Mol Biol; 2018; 1741():31-51. PubMed ID: 29392688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.